ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 6, 1999, Pages 1373-1378

  Para, Michael F ^a   Meehan, Patricia ^b,j   Holden Wiltse, Jeanne ^b   Fischl, Margaret ^c   Morse, Gene ^d   Shafer, Robert ^e   Demeter, Lisa M ^f   Wood, Kenneth ^g   Nevin, Tom ^h   Virani Ketter, Nzeera ^h,k   Freimuth, William W ⁱ  

^a OHIO STATE UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ PFIZER INC   (United States)

^j University Hospitals Clinic ^*  (United States)

^k VaxGen Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; DIDANOSINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

EID: 0033063976     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.6.1373     Document Type: Article

References (17)

1. D'Aquila, R. T., M. D. Hughes, V. A. Johnson, M. A. Fischl, J. P. Sommadossi, S. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, and M. S. Hirsh. 1996. Nevirapine, zidovudine, and didanosine compared to zidovudine, and didanosine in patients with HIV-1 infection. Ann. Intern. Med. 1214:1019-1030.
2. Davey, R. T., D. G. Chaitt, G. F. Reed, W. W. Freimuth, B. R. Herpin, J. A. Metcalf, P. S. Eastman, J. Falloon, J. A. Kovacs, M. A. Polis, R. E. Walker, H. Masur, J. Boyle, S. Coleman, S. R. Cox, L. Wathen, C. L. Daenzer, and H. C. Lane. 1996. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1657-1664.
3. DeJong, M. D., S. Vella, A. Carr, et al. 1997. High-dose nevirapine in previously untreated human immunodeficiency virus type-1 infected persons does not result in sustained suppression of viral replication. J. Infect. Dis. 175:966-970.
4. Demeter, L., R. Shafer, M. Para, G. Morse, W. Freimuth, T. Merigan, and R. Reichman. 1996. Delavirdine susceptibility of HIV-1 isolates obtained from patients receiving delavirdine monotherapy-ACTG 260, abstr. 322, p. 113. In Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections.
5. Dueweke, T. L., F. J. Kezdy, G. A. Waszak, M. R. Deibel, and W. G. Tarpley. 1992. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:27-30.
6. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. N. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
7. Freimuth, W. W., R. Davey, D. Batts, C. Lane, S. Cox, L. Wathen, B. Peel, C. Daenzer, G. Morse, D. Chaitt, et al. 1994. Phase II clinical trials of delavirdine mesylate combination therapy, abstr. 512B, p. 59. In Program and abstracts of the X International Conference on AIDS/V STD World Congress.
8. Green, S., M. F. Para, P. W. Daly, W. W. Freimuth, L. D. Getchel, C. A. Greenwald, and L. K. Wathen. 1998. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with delavirdine + Retrovir (ZDV) + Epivir (3TC), abstr. 12219. In Program and abstracts of the Twelfth World AIDS Conference.
9. Havlir, D., S. H. Cheeseman, H. M. McLaughline, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, M. Lamson, and D. D. Richman. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:537-545.
10. Japour, A., S. Fiscus, J.-M. Arduino, D. L. Mayers, P. S. Reichelderfer, and D. R. Kuritzkes. 1994. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291-2294.
11. Japour, A. J., D. L. Myers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
12. Montaner, J. S. G., P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. Wainberg, D. Smith, R. Robinson, D. Hall, M. W. Myers, J. Lange for the INCAS Study Group. 1998. A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS trial. JAMA 279:930-937.
13. Mulder, J., N. McKinney, C. Christopherson, J. Snisky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
14. Pharmacia & Upjohn Company. 1997. Delavirdine package insert. Pharmacia & Upjohn Company, Bridgewater, N.J.
15. Roxane Laboratories. 1998. Nevirapine package insert. Roxane Laboratories, Columbus, Ohio.
16. Saag, M. S., E. A. Emini, O. L. Laskin, et al. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
17. Staton, B. A., M. G. Johnson, J. M. Friis, and W. J. Adams. 1995. Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human serum. J. Chromatogr. Biomed. Appl. 668:99-106.